Coherus BioSciences Inc (NAS:CHRS)
$ 1.625 0 (0%) Market Cap: 186.43 Mil Enterprise Value: 407.24 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 06:15PM GMT
Release Date Price: $16.1 (+0.75%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good afternoon, everyone. My name is Balaji Prasad. I lead the specialty pharma coverage from Barclays, and thank you for dialing in to Barclays Global Health Care Conference. Continuing the specialty pharma track for the conference, I'm pleased to introduce the management of Coherus. So we have with us today both Dennis Lanfear, President of Coherus and CEO; and McDavid Stilwell, CFO.

So we may have just take a technical glitch while we get Denny to join us. There we are.

Thank you, Denny. So Denny, thanks for joining us and McDavid. I probably (inaudible) after the significant strategic shift that you initiated earlier this year, moving in away from biosimilars (inaudible) to biologics (inaudible). So also congratulations on -- in sharing the rolling submission for toripalimab.

Questions & Answers

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

So I think, obviously, that's a part where -- firstly, can you take us through the native as to why you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot